Moreover, administration of lovastatin for 2 weeks markof proteins including eNOS, and Ras-like proteins such as edly attenuated the endothelial dysfunction in both vessel Rho. Inhibition of Rho results in a 3-fold increase in eNOS types [7] . At that time, it wasn't clear whether enhanceand nitrite generation, since Rho is an inhibitor of NO ment of prostacyclin, nitric oxide, adenosine, or some generation [14] . other endothelium-derived mediator could account for this
The above mentioned molecular effects are certainly of endothelial preservation.
interest, but lack clinical relevance, unless they have a It wasn't until the early 1990s that some of the pieces in therapeutic significance in either the treatment of or the the puzzle began coming together. Around that time, prevention of disease states. The significance of the acute several multicenter clinical trials on the role of cholesterol effects of the statins in normocholesterolemic subjects in coronary heart disease were completed including the became apparent shortly thereafter when Endres et al.
[15] MRFIT study and the Framingham Heart Study. In the and Lefer et al. [16] showed that simvastatin protects MRFIT study [8] conducted in 361 662 men, serum against life-threatening disorders. Simvastatin was found to cholesterol was found to be closely correlated with death attenuate brain injury and cerebral infarct size in mice from ischemic heart disease. At a serum cholesterol of 300 subjected to cerebral ischemia [15] , and markedly limited mg / dl the coronary heart disease death rate was 17 per cardiac contractile dysfunction in rat hearts subjected to 1000, whereas at 150 mg / dl it was only three per 1000, a global myocardial ischemia and reperfusion [16] . In both decline of almost 600% [9] . By 1995, several small clinical of these studies, the cytoprotective effects of simvastatin trials with statins began appearing [10, 11] . In one case, were related to enhanced NO. In the former study, the Shepherd et al. [11] , showed that pravastatin decreased the effect was abrogated in mice having their eNOS gene 2 / 2 mortality rate from coronary heart disease by 28%. Treadeleted (i.e. eNOS ), and in the latter study, vascular sure et al. [10] actually studied the effect of a statin on NO levels were measured directly with a NO electrode. coronary vasodilator responses of patients having atheroThese studies called attention to the fact that the NO sclerosis. These results suggested that the statins preserved preserving effects of acute statin therapy actually translate NO-dependent functions of the coronary vascular endointo important tissue preserving actions in two vital organs, thelium, a finding rapidly confirmed by the work of Kinlay the brain and the heart. In the case of cerebral ischemia a et al. [12] . These studies coupled with the larger 4S study significant component of the beneficial effect was attribu-(Scandinavian Simvastatin Survival Study) involving 4444 ted to increased cerebral blood flow [15] and in the case of patients, reinforced the concept that statins significantly myocardial ischemia / reperfusion injury, a key effect apreduced the incidence of coronary heart disease [4] .
peared to be attenuation of neutrophil infiltration into the Moreover, the mechanism for the protective effects of the reperfused myocardium [16] . In both cases, these key statins was thought to involve endothelial preservation actions could be attributed largely to enhanced endothelial related to enhancing NO release from the endothelium.
NO generation. These studies provided strong evidence All of the above clinical and basic research studies were that statins could be considered as therapeutic agents in conducted in hypercholesterolemic or atherosclerotic subacute life-threatening disorders independently of their jects. The general feeling among these investigators was cholesterol lowering effects, even in the setting of northat these beneficial effects on the endothelium, possibly mocholesterolemia. In fact, the statins can now be considrelated to NO, were solely due to the cholesterol lowering ered as 'endogenous NO donors' or NO enhancing agents. effect of the statins (i.e. it was the cholesterol lowering per
There is an abundant literature demonstrating that physiose that resulted in vascular protection). The NO enhancing effect of the statins have attracted showed that simvastatin and lovastatin increased the halfwidespread interest. There is universal agreement on the life of the mRNA for eNOS from 13 to 38 h. This fact that statins enhance the machinery for synthesizing remarkable effect occurred following exposure to 1 mM NO (i.e. eNOS is upregulated). This enhanced expression statin treatment for only 48 h. In a follow-up study, statins of eNOS was first shown by Liao's laboratory [13, 14] for were shown to exert these salutary NO promoting effects simvastatin and mevastatin, and was confirmed in bovine by inhibiting the biosynthesis of L-mevalonate (the major aortic endothelial cells [19] . This work was extended to precursor of cholesterol) and of the isoprenoid lovastatin [20] , atorvastatin [19] , and fluvastatin [21] . geranylgeranylpyrophosphate (GGPP) [14] . GGPP is imMoreover, these positive results were found to occur in portant in the post-translational modifications of a variety human cells [13, 14, 19] in mice [22] , and in rats [21] . All of these studies show clear upregulation of eNOS mRNA, inflammatory stimuli including thrombin, leukotriene B 4 and several of them show eNOS protein to be significantly (LTB ), L-NAME, and platelet activating factor (PAF). 4 increased. Relevant to these data is the finding of Endres et Thrombin and L-NAME would be expected to primarily al. [15] that simvastatin increased the catalytic activity of activate the endothelium, whereas PAF and LTB would 4 calcium-dependent NOS in simvastatin-treated mice by 2-primarily activate leukocytes. The net result of statins to 3-fold. However, it is apparent that for the NO mediated would be a significant reduction in the number of transhypothesis of statin action to be validated, actual enhanced migrated leukocytes which is precisely what was found by NO levels need to be shown. This has recently been done both groups. In terms of the mechanism of this effect, using a direct NO electrode which specifically measures Pruefer et al. [28] showed that simvastatin attenuated the NO release from cells [23] . This has been reported by two up-regulation of the cell adhesion molecule P-selectin on separate groups using a specific NO electrode coupled with the mesenteric endothelium, an effect also observed for to a NO meter. Both groups studied pravastatin and simvastatin on the coronary endothelium in ischemia / simvastatin [16, 24] , one using cultured bovine aortic reperfusion [16] . Consistent with these findings was a endothelial cells (BAECs) [24] and the other using exreduction in leukocyte rolling flux [27] and leukocyte planted rat aortic segments [16] . In both cases, statins were rolling velocity [28] . Both of these events are early found to significantly increase NO generation by 2-to components of enhanced leukocyte-endothelium interac-3-fold, a response which was totally inhibited by the NOS tion and are regulated by the selectin family of adhesion inhibitor L-NAME. Thus, the NO releasing action is a glycoproteins, particularly P-selectin. Moreover, Romano common property of these two naturally occurring statins. et al. [29] recently observed that fluvastatin reduces Confirmation of the NO hypothesis of statin action is soluble P-selectin levels in hypercholesteromic patients. In provided by the fact that the statins do not protect in eNOS addition to modulating P-selectin, statins appear to exert deficient mice. This was first shown in mice subjected to similar down-regulatory effects on another endothelial cell stroke [15] , and later confirmed in mice subjected to adhesion molecule, ICAM-1 [29, 30] . However, while myocardial ischemia / reperfusion [25] . Moreover, the instatins exert an anti-inflammatory effect on endothelial cell crease in cerebral blood flow in mice given simvastatin adhesion molecules (i.e. P-selectin, ICAM-1), they also was abolished in eNOS deficient mice [22] as was the appear to have similar effects on leukocyte adhesion amelioration of leukocyte adherence to the microvascular molecules. Thus, simvastatin down-regulates CD18 (i.e. endothelium [26] appear to be dependent upon NO [16, 29] since they were Moreover, this NO enhancing effect of statins occurs at accompanied by either increased NO or increased nitrite clinically relevant doses of the statins. In one study [16] , levels indirectly related to enhanced NO. However, the the cardioprotective effect of simvastatin occurred at 25 most convincing demonstration that reduced leukocytemg / rat, a dose equivalent to 10 mg in a human subject, the endothelium interaction by statins is dependent upon NO, initial starting dose of this statin.
is that the statins failed to ameliorate the high leukocyte rolling and adherence in eNOS deficient mice [25] . Thus, statins appear to exert a significant portion of their cytoprotective effects via enhancing NO release and the 5. Effects of statins on leukocyte-endothelial resulting attenuation of leukocyte-endothelium interaction. interactions This effectively prevents neutrophil and monocyte mediated injury and retards atherosclerotic plaque formation. One of the key effects of the statins appears to be Furthermore, statins exert these effects independently of inhibition of leukocyte-endothelium interaction, a crucial their well known lowering of circulating cholesterol levels. anti-inflammatory action. This effectively attenuates the infiltration of leukocytes (particularly neutrophils) into inflamed regions, thus curtailing tissue injury in these areas. Several examples of local inflammation occur 6. Other potential vasculoprotective and following ischemia / reperfusion of organs (e.g. myocardial cytoprotective actions of statins ischemia / reperfusion, mesenteric ischemia / reperfusion, cerebral ischemia / reperfusion). In this regard, both fluvasAlthough it is clear that a major anti-inflammatory tatin [27] and simvastatin [28] were found to markedly action of the statins is to promote basal release of attenuate leukocyte adherence to mesenteric post-capillary endothelium-generated NO, this is not the only important venules. This occurred in response to a variety of procellular or molecular effect of the statins [31] . Other important effects of the statins can be categorized as found to attenuate smooth muscle cell proliferation [39] . follows:
This effect could be important in reducing atherogenesis and in limiting the extent of restenosis in blood vessels (a) Anti-oxidant following angioplasty. A recent study has clearly demon-(b) Anti-thrombotic strated that simvastatin induces angiogenesis via an Akt-(c) Vasculoprotective dependent mechanism [40] . The therapeutic potential of (d) Angiogenic angiogenesis in cardiovascular diseases such as myocardial (e) Membrane transport ischemia and stroke is great. Simvastatin was also shown to attenuate endothelial cell apoptosis, another cytoprotecOne important action of the statins is their ability to tive effect of the statins [40] . Once again, these properties scavenge oxygen-derived free radicals. A variety of statins are also in common with those of nitric oxide [41] . Very exhibit this property including simvastatin [32] , fluvastatin recently, statins were shown to influence sarcolemmal 1 1 [33, 34] , atorvastatin, pravastatin and cerivastatin [35] , Na / K pump function, an effect which may influence 1 although pravastatin has been reported to be not so contractility of cardiac myocytes via modulation of Na / 1 effective under all conditions [33] . Generally, the statins K pump current [42] . Thus, most of these additional scavenge superoxide in a dose-dependent manner [33, 35] .
anti-inflammatory effects of the statins are consistent with Others have reported that fluvastatin also scavenges hytheir NO enhancing action, and in fact these effects could droxyl radicals [34] . Some of the superoxide scavenging be partially due to the NO enhancing action of the statins. actions of statins may be due to their reduction in the biosynthesis of isoprenoids, and since some of the superoxide generators (e.g. NADPH oxidase) are iso-7. Potential usefulness of statins in other prenylated proteins, this effect of the statins would reduce cardiovascular disorders the effectiveness of these free radical generators.
Of course, the reduction in superoxide radical formation The statins of course are designed to reduce LDL by statins would act to enhance the bioavailability of NO, cholesterol levels and thus to exert an atherosclerotic and thus potentiate the effectiveness of endothelium-generpreventing or delaying effect. This has been amply demonated NO, a key aspect of the tissue-protective effects of the strated in major clinical trials in humans, mentioned earlier statins.
in this review (Section 1). What has emanated from these A second additional effect of the statins can be categorstudies is a clear consensus that cardiovascular events are ized as an anti-thrombotic effect. This action occurs in reduced in patients on a daily maintenance dose of a statin several ways. First, simvastatin has been shown to reduce (i.e. usually 20-80 mg per day). These findings have levels of plasminogen activator inhibitor-1 (PAI-1) in recently been extended in the laboratory to animals having human vascular smooth muscle and endothelial cells and to normal circulating cholesterol levels. Some of these key increase expression of tissue plasminogen activator (tPA) effects (e.g. attenuation of myocardial ischemia / reperfuin these same human vascular cells [36] . The net result of sion injury and amelioration of stroke induced neurological these two effects would be to markedly tilt the fibrinolytic deficits) have been discussed in Section 3 of this paper. balance in the blood vessel wall toward increased fibThese effects are related to a significant blunting of the rinolytic activity. Additionally, simvastatin has been shown endothelial dysfunction occurring early in these disorders. to reduce in vivo clotting activation in healthy patients Clearly, endothelial dysfunction is a prominent feature in presumably due to reduced tissue factor (TF) expression other cardiovascular diseases, including diabetes mellitus, on monocytes [37] . This effect also occurred in a dosehypertension, and graft vessel disease following organ dependent manner over the clinical range of statins used in transplantation. hyperlipidemic patients (i.e. 10-80 mg). Moreover, these It is therefore not surprising that statins ameliorate the anti-thrombotic effects can synergize with the anti-platelet pathogenesis of these disease states. Earlier studies have aggregating effect of NO, which also occurs in response to shown that statins lower cardiovascular event risk reducstatin therapy.
tion in diabetic patients, to even a greater extent than in Thirdly, the statins exert additional effects on vascular non-diabetic controls [43, 44] . More recently, further analycells (i.e. smooth muscle and endothelial cells). One such sis of the Scandinavian Simvastatin Survival Study has effect is the reduction in the precursor of endothelin-1 (i.e. revealed that simvastatin treated diabetic patients exhibited pre-proET-1) as well as in the synthesis of ET-1 [19] . This a 42% reduction in risk of major coronary events, and a endothelin blunting effect occurred in response to either 43% reduction in coronary event related mortality [45] . atorvastatin or simvastatin, and was reversed by mevaloThis is related to improved endothelial function and higher nate but not by cholesterol. However, in a clinical study, NO bioavailability in patients with type II diabetes mellitus fluvastatin failed to reduce circulating levels of ET-1 while [46] . Finally, in genetically diabetic mice (db / db mice), it lowered circulating cholesterol levels [38] . Along these simvastatin was found to attenuate the severity of myocarlines, plasma from fluvastatin-treated patients has been dial ischemia reperfusion injury as well as to reduce Of course, caution must be applied to these data until large prompted one group to conclude that 'nonlipid properties tions by attenuating leukocyte-endothelial cell interaction.
Simvastatin preserves the ischemic-reperfused myocardium in nor-
The net result of these important endothelial preserving mocholesterolemic rat hearts. Circulation 1999;100:178-184.
actions is a cardiovascular system that is capable of 
